Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability

JAMA. 2022 May 3;327(17):1647-1648. doi: 10.1001/jama.2022.5959.

Authors

Ryan P Knox¹, Aaron S Kesselheim², Ameet Sarpatwari²

Affiliations

¹ Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts.
² Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

PMID: 35426909
DOI: 10.1001/jama.2022.5959

No abstract available

MeSH terms

Costs and Cost Analysis
Drug Costs* / legislation & jurisprudence
Drug Industry* / economics
Drug Industry* / legislation & jurisprudence
Health Services Accessibility* / economics
Health Services Accessibility* / legislation & jurisprudence
Medicaid* / economics
Medicaid* / legislation & jurisprudence
United States